Gritstone bio up after update on cancer therapy trial data

Gritstone bio

10/11/2022 18:38

** Shares of Gritstone bio Inc  GRTS.O  rise 11.5% to $2.62 
    ** Co announces updated overall survival results from an
early-to mid-stage study of its experimental cancer
immunotherapy for treatment of advanced solid tumors
    ** Co says 6 of 13 treated patients had molecular response
and observed median overall survival in the group will now
exceed 22 months 
    ** Data compares with observed median overall survival in
treatment group exceeding 18 months, which was reported in May 
    ** Therapy is being evaluated in patients with a type of
colorectal cancer, sometimes called as colon cancer, who have
received at least two prior lines of therapy 
    ** Overall survival represents testing the drug to see
whether it is helping patients live longer   
    ** Including session's move, stock down ~80% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))